Raymond James raises target for Scholar Rock stock from USD 65.00 to USD 72.00

Published on 10/05/2026 at 02:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA approved ISEMBYLD on September 11, 2026 for spinal muscular atrophy. Scholar Rock stock last traded EUR 44.50 on September 23, 2026, below EUR 44.69.

SRRK, US80706P1030, Illustration mit AI erstellt.

Raymond James raised its price target for Scholar Rock stock from USD 65.00 to USD 72.00 on September 14, 2026, while maintaining a Strong Buy rating, Investing.com reported. The revision followed FDA approval of ISEMBYLD, giving the company a commercial product in spinal muscular atrophy.

Approval changes the story

According to the company filing dated September 11, 2026, the FDA approved ISEMBYLD, also known as apitegromab-mstn, for adults and children at least 2 years old with spinal muscular atrophy who receive SMN2-targeted treatment, SEC.gov reported. The approval moves Scholar Rock from a development-stage narrative toward launch execution, making manufacturing, reimbursement and patient uptake the next measurable issues.

Scholar Rock describes itself as a biopharmaceutical company focused on therapies targeting protein growth-factor signaling. Its lead product therefore carries the commercial weight of the company, while the pipeline offers additional research optionality.

Losses remain a key counterweight

Scholar Rock reported a net loss of USD 109.90 million in the second quarter of 2026, or USD 0.84 per diluted share, compared with a USD 105.51 million loss and USD 0.83 loss per share in the first quarter, according to StockTitan. Research and development expense reached USD 58.23 million in the second quarter, while selling, general and administrative expense was USD 50.67 million.

The figures show why the approval is important but not sufficient by itself. A wider quarterly loss alongside a newly approved therapy leaves the valuation tied to the speed of commercialization rather than to established revenue.

Target implies a higher valuation

Raymond James' USD 72.00 target stands above its previous USD 65.00 target, a USD 7.00 increase, and its Strong Buy rating rests on the approved product's commercial potential, Investing.com reported on September 14, 2026. BMO Capital separately reiterated an Outperform rating and a USD 76.00 target on September 10, 2026, citing physician survey data on potential use of apitegromab, Investing.com reported.

Tradegate quote remains dated

Scholar Rock stock was last at EUR 44.50 at Tradegate on September 23, 2026, down 0.43 percent versus the Tradegate close of EUR 44.69 on September 22, 2026. Price source: substitute price Tradegate, Lang & Schwarz without data set.